Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
85 participants
OBSERVATIONAL
2021-03-19
2022-04-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Factors associated with a higher risk of death in patients with SARS-CoV-2 include age and low circulating lymphocyte counts. Significant lymphopenia is indeed frequently observed in patients with severe COVID-19 and both phenotypic and functional changes in antiviral T cells have been correlated with the severity of COVID-19.
The thymus, the organ that produces T lymphocytes, undergoes progressive physiological involution with age. However, in the elderly, rare cases of thymic hyperplasia are reported in autoimmune diseases or cancers, or are observed in response to deep lymphopenia, whether or not associated with sepsis.
This cohort of patients treated for a SARS-CoV-2 infection could allow to better understand the role of the thymus in this pathology.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
NCT04362865
T Cells Response to SARS COV 2 Peptides
NCT04573348
Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals
NCT04871165
Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras
NCT04771013
Immunity to Infection in Healthy Participants and Participants With Cancer
NCT05787964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case : COVID-19 positive patients
patients hospitalized for COVID-19 infection
Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region
DNA extraction from blood samples, PCR and Sequencing
Blood sample
Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
CT Scan
Thymus and lung imaging
Bronchial fibroscopy
Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
Control : COVID-19 negative patients
patients hospitalized for other reasons
Blood sample
Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
CT Scan
Thymus and lung imaging
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Single-Nucleotide Polymorphisms (SNP) within the TCRA/D region
DNA extraction from blood samples, PCR and Sequencing
Blood sample
Dosage of sj/βTREC ratio, lymphocytes, cytokines and chemokines.
CT Scan
Thymus and lung imaging
Bronchial fibroscopy
Bronchoalveolar lavage in mechanically ventilated patients for dosage of recent thymic emigrants in lungs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with confirmed COVID-19 infection
* Hospitalized for COVID-19 infection
* Having signed a written informed consent form
* Affiliation to the social security system
Controls :
* Non-COVID-19 patients
* Hospitalized for other reasons
* Age and sex-matched controls
* Having signed a written informed consent form,
* Affiliation to the social security system
Exclusion Criteria
* HIV, Hepatitis B or Hepatitis C
* Pregnant or breastfeeding women
* A mental or linguistic inability to understand the study
* Patient under protection of the adults (guardianship, curators or safeguard of justice)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CMC Ambroise Paré
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CMC Ambroise Paré
Neuilly-sur-Seine, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020/06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.